Director, Global HEOR - Oncology at Bristol-Myers Squibb

Princeton, New Jersey, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, OncologyIndustries

Requirements

An advanced degree (PhD/MD/PharmD/MS/MPH) in Health Economics, Outcomes Research, Econometrics, Epidemiology, Public Health or related discipline is highly preferred
6+ years of professional experience, with at least 3-5 years in the biopharmaceutical industry, or with a company that provides services to the biopharmaceutical industry
Experience in executing an HEOR book of work and working in a matrix organization to support worldwide value access for a medicine is required
An exemplary record of HEOR deliverables and peer-reviewed publications
Experience managing patient registries or prospective observational studies is preferred
Experience in supporting regulatory submissions is preferred
Very strong written and verbal communication skills and be capable of distilling the essential elements of complex issues for senior internal and external stakeholders and scientific and non-scientific audiences alike
Knowledge of oncology is strongly preferred

Responsibilities

Develop worldwide health economic & outcomes research strategy to support BMS oncology products strategy and value proposition across early development to post launch lifecycle
Design and execute HEOR studies with study concept, protocol, analysis plan, study report, data dissemination, for research including but not limited to systematic literature reviews, disease burden, patient reported outcomes, real-world treatment patterns and outcomes, economic modeling, prospective observational studies and comparative effectiveness studies in the oncology therapeutic area
Engage and collaborate with oncology asset level matrix teams, including market access, clinical development, medical affairs, regulatory, biostatistics to ensure full alignment and integration HEOR evidence generation plan to support regulatory, market access and brand strategic imperatives and objectives
Represent HEOR at cross-functional team matrix such as Development Team and Global Brand Team
Develop and manage Global HEOR Book of Work to ensure optimal allocation and prioritization of budgetary resources to support oncology asset level objectives
Ensure compliance with BMS SOPs and guidance in HEOR study conduct
Maintain and develop strong partnership with external key opinion leaders in clinical, health economics, and outcomes research
Manage prospective observational studies/patient registries as the Scientific Lead, as needed

Skills

HEOR

Health Economics

Outcomes Research

Economic Modeling

Systematic Literature Reviews

Real-World Evidence

Patient Reported Outcomes

Observational Studies

Comparative Effectiveness

Oncology

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free